Role of Oxytocin in Myocardial Infarction
- Registration Number
- NCT03001635
- Lead Sponsor
- Sheba Medical Center
- Brief Summary
60 patients admitted to this ICCU at the Sheba medical Center will be randomly divided in to 2 groups. one group will receive the conventional treatment while the second group will receive the conventional treatment plus oxytocin infusion for 48 hours. all participants will undergo echo and cMRI during hospitalization.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
- age > 18 years
- current diagnosis of ST elevation myocardial infarction
- no previous episodes of acute coronary syndrome
- agreed to enter research
Exclusion Criteria
- age < 18 years
- congestive heart failure (acute or chronic)
- cardiomyopathy
- life threatening arrhythmia at presentation
- previous LV dysfunction
- hypotension (systolic < 100mmHg, diastolic<50mmHg, 15% less than patients normal values)
- tachycardia - pulse > 100bpm
- bradycardia - pulse < 55 ppm
- killip 3 or 4 at presentation
- current use of nitrates
- pregnancy
- females - history of pathological GU bleeding
- inability to give consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description conventional treatment only Placebos 26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers \& ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo. conventional treatment and oxytocin Oxytocin 26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers \& ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
- Primary Outcome Measures
Name Time Method final infarction size 1 week all patients will undergo an cMRI after 7 days
- Secondary Outcome Measures
Name Time Method Ejection fraction 48 hours all patients will undergo echocardiography exam during the first 48 hours